SARS treatment. Interferon shows promise in monkeys.
Enserink
Martin
M
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use*; D008168:Lung / Q000473:pathology; D008252:Macaca fascicularis; D011092:Polyethylene Glycols; D011994:Recombinant Proteins; D045473:Severe acute respiratory syndrome-related coronavirus / Q000187:drug effects / Q000276:immunology; D045169:Severe Acute Respiratory Syndrome / Q000188:drug therapy* / Q000473:pathology / Q000517:prevention & control* / Q000821:virology
D000911:Antibodies, Monoclonal; D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a